In Phase A, participants will get different doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants might be enrolled in the determined monotherapy dosign routine. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In Segment https://samuelw110jue3.blogproducer.com/profile